Skip to content

Study · Not a test of the peptide alone · 2005

2 results

Interactions of human melanocortin 4 receptor with nonpeptide and peptide agonists.

Pogozheva ID, Chai BX, Lomize AL, Fong TM, Weinberg DH, Nargund RP, Mulholland MW, Gantz I, Mosberg HI

Biochemistry1 Aug 2005Cited by 72 (Europe PMC)

PMID16114870 (opens in a new tab)PMCIDPMC2532597 (opens in a new tab)DOI10.1021/bi0501840 (opens in a new tab)PepBankPUB-16114870
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 01LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cells)Mechanism

    In cells expressing hMC4R mutants, the binding affinity and potency of the linear peptide agonist NDP-MSH were substantially reduced only in the D126A and H264A mutants.

    In plain wordsIn cells, NDP-MSH bound and worked much less well only on two altered forms of the MC4 receptor.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseNDP-MSH binding affinity and potency at hMC4R mutants
    Study

    n: not reported in source

    cells expressing hMC4R alanine mutants
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    By contrast, binding affinity and potency of the linear peptide agonist NDP-MSH were substantially reduced only in D126A and H264A mutants.
    1 context sentence
    Summary · context
    Specific interactions of human melanocortin-4 receptor (hMC4R) with its nonpeptide and peptide agonists were studied using alanine-scanning mutagenesis.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  2. 02Computer modelNot a test of Melanotan I (afamelanotide) aloneIn silicoMechanism

    In receptor-ligand models, all pharmacophore elements of the small-molecule agonists spatially overlapped with the key residues of the linear peptide NDP-MSH.

    In plain wordsIn computer models, the small-molecule agonists matched the key parts of NDP-MSH in the MC4 receptor.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableOverlap of small-molecule agonist pharmacophores with NDP-MSH key residues
    Study

    n: not reported in source

    three-dimensional hMC4R-agonist models
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    In the models, all pharmacophore elements of small-molecule agonists are spatially overlapped with the corresponding key residues (His(6), d-Phe(7), Arg(8), and Trp(9)) of the linear peptide
    1 context sentence
    Summary · context
    Specific interactions of human melanocortin-4 receptor (hMC4R) with its nonpeptide and peptide agonists were studied using alanine-scanning mutagenesis.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.